

Zambia Support for Measles-Rubella Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Zambia				
2. Grant number: 1718-ZMB-09a-X / 12-ZMB-8b-Y				
3. Date of Decision Letter: 22 December 2017				
4. Date of the Partnership Framework Agreement: 22 October 2014				
5. Programme title: New vaccine support (NVS), Measles-Rubella Second Dose Routine				
6. Vaccine type: Measles-Rubella				
7. Requested product presentation and formulation of vaccine: Measles Rubella, 10 dose(s) per vial, LYOPHILISED				
8. Programme duration¹: 2012 - 2018				
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement)				
	2012-2016	2017	2018	Total ²
Programme Budget (US\$)	US\$615,018	US\$231,000	US\$90,500	US\$936,518
10. Vaccine introduction grant (US\$): US\$ 551,500 disbursed in 2012 to UNICEF. US\$ 775 refund of unspent funds received in 2016.				
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ³				
Type of supplies to be purchased with Gavi funds in each year	2012-2016	2017	2018	
Number of Measles-Rubella vaccines doses		824,100	322,100	
Annual Amounts (US\$)	US\$615,018	US\$231,000	US\$90,500	
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.				
13. Self-procurement: Not applicable				
14. Co-financing obligations: Not applicable				

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the amount that Gavi has approved.

15. Operational support for campaigns: Not applicable		
16. Additional reporting requirements:		
Reports and other information	Due dates	
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May	
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat	
17. Financial clarifications: Not applicable		
18. Other conditions:		
Country has presented an official request to Gavi to switch from measles vaccine to measles- rubella vaccine for the routine second dose with country funding the equivalent cost of the rubella component. As such, country will make the required payments to UNICEF SD as indicated in the table below.		
	2017	2018
Number of doses of vaccines for Measles Second Dose approved by Gavi.	824,100	322,100
Amount for vaccines approved by Gavi in US\$ (excluding freight and insurance).	222,507	86,967
Number of doses of Measles-Rubella vaccine that can be purchased with Gavi support.	360,044	140,723
Number of doses of Measles-Rubella vaccine to be funded by country.	464,056	181,377
Amount for Measles-Rubella vaccines to be funded by country (excluding freight and insurance).	286,787	112,091
<p>In the case of procurement through UNICEF, Gavi-funded vaccines will be purchased only after receipt of full payment of the respective amounts due from Country for the number of doses as indicated in this Decision Letter. Country is required to submit a request for a Cost Estimate to UNICEF, with a clear reference to the approval code and approval year. Country will inform Gavi Secretariat when payment of the respective amount due under this Cost Estimate has been fully made to UNICEF.</p> <p>In the event that country wishes to revert to measles vaccine, country should inform UNICEF and Gavi immediately in order to agree on an appropriate arrangement.</p>		

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
22 December 2017